Frost & Sullivan Commends eClinicalWorks CCMR®, a Comprehensive Analytical Platform for Population Health Management

MOUNTAIN VIEW, Calif., Sept. 8, 2014-- Based on its recent analysis of the population health management industry, Frost & Sullivan recognizes eClinicalWorks with the 2014 North America Frost & Sullivan Award for Enabling Technology Leadership. eClinicalWorks has reinforced its prominence in the ambulatory healthcare IT solutions market by developing the Care Coordination Medical Record® (CCMR®), a Web-based, dynamic and highly cross-functional platform for population health management and coordinated care.

CCMR® is a combination of technology platforms that extensively mine clinical information available to physicians and generate intelligent and actionable insights for care coordination and planning. It securely bridges pockets of patient information available through ambulatory electronic health records (EHRs), hospital information systems (HIS), and payer systems to generate an accurate picture of patient engagement across the continuum of care. Accountable care organizations (ACOs) and physicians use these insights to assess risk and develop accurate care models, resulting in the improvement of clinical outcomes and the reduction of healthcare costs.

CCMR® is a one-of-a-kind population health management tool that offers intelligent closed-loop analytics for multi-dimensional insights into patient behavior and community health dynamics. This is made possible through the bundling of important functions, including the integration of information systems, management of the physician referral network, and evaluation of diverse data streams to build precise care models.

"CCMR® boasts other distinct advantages such as a remarkable flexibility and ability to be customized to clients' needs," said Frost & Sullivan Research Analyst Bhargav Rajan. "However, one of the truly distinguishing features of the CCMR® platform is that it is EHR system-agnostic. This feature is particularly attractive in markets as fragmented as the U.S. HIS market."

The potential of the CCMR® platform received early validation with eClinicalWorks' ground-breaking partnership with New York City's Primary Care Information Project (PCIP) in 2007. The project was an initiative by the New York City administration to develop a system that would monitor and rapidly respond to unanticipated events. The system would then progressively identify and record changing morbidity and lifestyle patterns so health officials could determine disease burden, monitor outbreak of epidemics by geographical locations, and formulate care plans based on lifestyle diseases.

Since its implementation in 2008 and serving more than 3 million New Yorkers, the Hub, as the New York City analytics system is called, has led to better healthcare servicing of tens of thousands of patients through diabetes monitoring, cardiovascular management, and control of tobacco consumption. New York City estimates that the analytics platform has facilitated an impressive 290 percent increase in preventive screenings. Furthermore, the city has initiated a number of community-oriented healthcare programs with the analytical support offered by the Hub.

Some of the exceptional features of the CCMR® system include its ability to parse through vast amounts of data; intelligent and context-based analysis of health information; assessment and stratification of patients based on the level of risk; and proactive engagement of patients.

"The CCMR® system has been widely recognized for its intuitive and easy-to-use interface, superior data visualization features, and provision of meaningful and actionable analysis," noted Rajan. "Together, these features aid better resource management, minimize hospital visits, and reduce costs to providers as well as patients."

The scale of success of the CCMR® platform is already apparent from its wide-scale adoption in a short span of time, including with more than 50 Centers for Medicare & Medicaid Services (CMS)-recognized ACOs. Due to its effectiveness in informed decision-making, risk management, healthcare quality improvement, patient engagement and healthcare cost reduction, the CCMR® has already been deployed in numerous healthcare organizations in the United States in less than two years since its launch.

Use of eClinicalWorks CCMR is already showing significant results on cost and quality, with some customers seeing a reduction in emergency room visits by 50%, hospital readmissions going down by 22%, short-term complications due to diabetes being lowered by 37%, and hospitalizations due to congestive heart failure decreasing by 22%.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products, but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient's technology.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About eClinicalWorks
eClinicalWorks® is a privately-held leader in ambulatory healthcare IT solutions. With clients across all 50 states using its solutions, customers include ACOs, physician practices, out-patient departments of hospitals, health centers, departments of health and convenient care clinics. Ten eClinicalWorks customers have received the prestigious HIMSS Davies Awards during the past six years, honoring excellence in electronic health record implementation. The company is second largest in the country for e-prescribing. Based in Westborough, Mass., eClinicalWorks has additional offices in New York City, Chicago, California and Georgia. For more information, please visit www.eclinicalworks.com, Facebook, Twitter or call 866-888-6929. 

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.